Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,204 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control I Clear all
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

NCT07128615
View directory record Official record
Conditions
Influenza A
Interventions
AZD4117, AZD5315, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
14
States / cities
Long Beach, California • Rolling Hills Estates, California • Miami Lakes, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Not applicable Interventional

The Liver Health Study for Patients with NAFLD

NCT03151798
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
Interventions
Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies
Behavioral · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
22 Years to 65 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 2 Interventional

Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy

NCT01019187
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Quality of Life Assessment, Questionnaire Administration, Placebo, Fatigue assessment and management, Sleep disorder therapy, Armodafinil, Management of Therapy, Cognitive Assessment, Management of therapy and complications, Fatifue assessment and management
Procedure · Other · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Health Intervention in Increasing HPV Vaccine Coverage Among Young Adult Gay and Bisexual Men

NCT02835755
View directory record Official record
Conditions
Healthy Subject
Interventions
Educational Intervention, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 22, 2026, 4:53 PM EDT
Not listed No phase listed Observational

Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.

NCT00910884
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, therapeutic dietary intervention
Other · Procedure
Lead sponsor
Brabant Research
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Spokane Valley, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 22, 2026, 4:53 PM EDT
Recruiting Not applicable Interventional

Digital Cognitive Behavioral Treatment of Insomnia in Youth: An RCT Examining Feasibility, Acceptability, and Efficacy of NiteCAPP Jr

NCT07091149
View directory record Official record
Conditions
Insomnia
Interventions
CBT-I
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 4:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma

NCT01192555
View directory record Official record
Conditions
Neuroblastoma
Interventions
Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells, Cytoxan
Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

NCT02363738
View directory record Official record
Conditions
Bipolar Depression
Interventions
Infliximab, Saline
Drug · Other
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

NCT00000958
View directory record Official record
Conditions
HIV Infections
Interventions
MTP-PE/MF59, Env 2-3
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Results available

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

NCT02113878
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma of Larynx, Cancer of Nasopharynx
Interventions
BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Pain Alleviating Strategies During Allergy Shots

NCT04181632
View directory record Official record
Conditions
Immunotherapy, Allergy
Interventions
Buzzy Bee with Ice pack, Buzzy Bee without Ice pack, Shot Blocker
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
4 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression

NCT00194116
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium ER, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 22, 2026, 4:53 PM EDT
Withdrawn Phase 2 Interventional

Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy

NCT02252978
View directory record Official record
Conditions
Prostate Cancer
Interventions
ciprofloxacin, placebo, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

NCT00000822
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine, Didanosine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 4:53 PM EDT
Enrolling by invitation Not applicable Interventional

Visual Outcomes in Patients Contralaterally Implanted With PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro

NCT07076277
View directory record Official record
Conditions
Cataract, Multifocal Intraocular Lens
Interventions
Clareon PanOptix Pro and Clareon Vivity Intraocular Lens, Clareon PanOptix Pro Intraocular Lenses
Device
Lead sponsor
Brian Shafer
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Alexandria, Minnesota • Bozeman, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 22, 2026, 4:53 PM EDT
Terminated Phase 3 Interventional

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

NCT00014651
View directory record Official record
Conditions
Pancreatic Cancer, Perioperative/Postoperative Complications
Interventions
vapreotide, conventional surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
18
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

Ampicillin for DYT-1 Dystonia Motor Symptoms

NCT01433757
View directory record Official record
Conditions
DYT-1, Dystonia
Interventions
Ampicillin, Sugar pill
Drug
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 22, 2026, 4:53 PM EDT
Terminated Not applicable Interventional

Electrical and Formocresol Pulpotomy in Primary Molars

NCT01622153
View directory record Official record
Conditions
Reversible Pulpitis, Caries
Interventions
Formocresol application after pulpotomy preparation, GENTLEray 980 Soft Tissue diode laser
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
3 Years to 8 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 22, 2026, 4:53 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Inflammatory and Metabolic Responses to Long-term Dietary Supplementation With Anthocyanin-rich Blend

NCT04637945
View directory record Official record
Conditions
Anthocyanins
Interventions
ACRB, Placebo
Dietary Supplement · Other
Lead sponsor
Pharmanex
Industry
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

NCT01817075
View directory record Official record
Conditions
Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection, Myeloid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Months to 21 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
53
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial

NCT00852592
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Episode
Interventions
7000lux broad-spectrum light, 50lux dim red light
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 3 Interventional

Aripiprazole in Patients With Acute Mania

NCT00095511
View directory record Official record
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
38
States / cities
Tuscaloosa, Alabama • Scottsdale, Arizona • Cerritos, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VivaGel™ in Healthy Young Women

NCT00331032
View directory record Official record
Conditions
Herpes Simplex II
Interventions
3% w/w SPL7013 Gel, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 22, 2026, 4:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants

NCT01809431
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 22, 2026, 4:53 PM EDT